Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380724 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL476051 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL11105656 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Benzene SCHEMBL28251054 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Hydrochloric Acid SCHEMBL28467903 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Hydrochloric Acid SCHEMBL28467902 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Hydrochloric Acid SCHEMBL30487171 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Bromide SCHEMBL7413848 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Bromide SCHEMBL7413853 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Hydrochloric Acid SCHEMBL28467019 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15HTTUBE2TASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| WO-2020230780-A1 | Ras INHIBITORY PEPTIDE | 一丸ファルコス株式会社 | 2020-11-19 | — | — | WO | claimed |
| US-20150337018-A1 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2015-11-26 | — | — | US | claimed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | claimed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | claimed |
| WO-2004050685-A2 | ANTIFUNGAL THERAPEUTIC AGENTS | ADAPTIVE THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260062692-A1 | COMPOSITIONS AND METHODS FOR THE IMMOBILIZATION OF ENZYMES USING CROSSLINKED BIOMOLECULAR CONDENSATES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-1965826-A2 | MNTF DIFFERENTIATION AND GROWTH OF STEM CELLS | Genervon Biopharmaceuticals LLC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1959981-A2 | ANTI-CONNEXIN COMPOUNDS AND THERAPEUTIC USES THEREOF | Coda Therapeutics Limited (NZ) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008057609-A2 | METHODS OF TREATING NEURONAL DISORDERS USING MNTF PEPTIDES AND ANALOGS THEREOF | GENERVON BIOPHARMACEUTICALS LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007058982-A2 | MNTF DIFFERENTIATION AND GROWTH OF STEM CELLS | GENERVON BIOPHARMACEUTICALS LLC (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006134494-A2 | ANTI-CONNEXIN COMPOUNDS AND THERAPEUTIC USES THEREOF | CODA THERAPEUTICS LIMITED (NZ) | 2006-12-21 | — | — | WO | disclosed |
| WO-2004050685-A2 | ANTIFUNGAL THERAPEUTIC AGENTS | ADAPTIVE THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | SMN1; SMN2 4067/4885ALOX15 4148/4885HTT 4183/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | SMN1; SMN2 4620/4885ALOX15 1078/4885HTT 4236/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | SMN1; SMN2 1799/4885ALOX15 2838/4885HTT 4721/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | SMN1; SMN2 2235/4885ALOX15 3434/4885HTT 4696/4885 |
| US-20260062692-A1 | COMPOSITIONS AND METHODS FOR THE IMMOBILIZATION OF ENZYMES USING CROSSLINKED BIOMOLECULAR CONDENSATES | ADH5, ADH1C, ADH1A | SMN1; SMN2 3542/4885ALOX15 273/4885HTT 3714/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | SMN1; SMN2 2679/4885ALOX15 2096/4885HTT 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.